• Compass Therapeutics to Participate in Upcoming Investor Events

    Источник: Nasdaq GlobeNewswire / 30 авг 2023 07:00:00   America/Chicago

    BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023.

    Details are as follows:

    Citi’s 18th Annual BioPharma Conference
    Location: Boston, MA
    Format: 1x1 Meetings
    Date: Thursday, September 7

    H.C. Wainwright 25th Annual Global Investment Conference
    Location: New York, NY
    Format: Presentation
    Date: Monday, September 11
    Time: 4:00 PM ET
    Webcast Link: https://journey.ct.events

    Cantor Fitzgerald Global Healthcare Conference
    Location: New York, NY
    Format: Fireside Chat
    Date: Wednesday, September 27
    Time: 2:25-2:55 PM ET
    Webcast Link: https://wsw.com/webcast/cantor19/cmpx

    Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

    About Compass Therapeutics
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

    Investor Contact
    ir@compasstherapeutics.com

    Media Contact
    Anna Gifford, Communications Manager
    media@compasstherapeutics.com
    617-500-8099


    Primary Logo

Опубликовать